Cordatus Wealth Management LLC Purchases 1,791 Shares of Johnson & Johnson (NYSE:JNJ)

Key Points

• Cordatus Wealth Management LLC increased its holdings in Johnson & Johnson by 5.6%, owning 33,669 shares valued at approximately $5.58 million.
• In the latest quarterly earnings report, Johnson & Johnson exceeded analysts' expectations with an EPS of $2.77 and revenue of $23.74 billion, a 5.8% year-over-year increase.
• The company declared a quarterly dividend of $1.30, which reflects a 3.11% dividend yield, and has a payout ratio of 55.61%.

Cordatus Wealth Management LLC increased its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 5.6% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 33,669 shares of the company's stock after acquiring an additional 1,791 shares during the quarter. Johnson & Johnson makes up about 1.5% of Cordatus Wealth Management LLC's holdings, making the stock its 16th largest position. Cordatus Wealth Management LLC's holdings in Johnson & Johnson were worth $5,583,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Northern Trust Corp grew its position in shares of Johnson & Johnson by 12.3% in the fourth quarter. Northern Trust Corp now owns 30,813,175 shares of the company's stock valued at $4,456,201,000 after purchasing an additional 3,363,235 shares in the last quarter. Bank of New York Mellon Corp grew its position in shares of Johnson & Johnson by 26.4% in the first quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company's stock valued at $3,844,580,000 after purchasing an additional 4,842,582 shares in the last quarter. Invesco Ltd. grew its position in shares of Johnson & Johnson by 6.5% in the fourth quarter. Invesco Ltd. now owns 19,126,079 shares of the company's stock valued at $2,766,014,000 after purchasing an additional 1,171,975 shares in the last quarter. Massachusetts Financial Services Co. MA grew its position in shares of Johnson & Johnson by 2.5% in the first quarter. Massachusetts Financial Services Co. MA now owns 18,282,410 shares of the company's stock valued at $3,031,955,000 after purchasing an additional 448,666 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its position in shares of Johnson & Johnson by 4.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 14,773,493 shares of the company's stock valued at $2,136,390,000 after purchasing an additional 636,430 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on JNJ. Guggenheim reiterated a "neutral" rating and issued a $167.00 price target (up from $164.00) on shares of Johnson & Johnson in a research report on Thursday, July 17th. The Goldman Sachs Group upgraded Johnson & Johnson from a "neutral" rating to a "buy" rating and boosted their target price for the stock from $157.00 to $172.00 in a research report on Wednesday, April 9th. Bank of America boosted their target price on Johnson & Johnson from $161.00 to $175.00 and gave the stock a "neutral" rating in a research report on Thursday, July 17th. Benchmark upgraded Johnson & Johnson to a "strong-buy" rating in a research report on Thursday, April 24th. Finally, Leerink Partnrs cut Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, May 13th. Nine research analysts have rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, Johnson & Johnson has an average rating of "Moderate Buy" and a consensus target price of $174.50.

Johnson & Johnson Trading Up 1.6%

Shares of NYSE JNJ traded up $2.59 during midday trading on Friday, reaching $167.33. The company had a trading volume of 8,914,735 shares, compared to its average volume of 8,384,981. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. The firm's fifty day moving average price is $157.46 and its 200-day moving average price is $156.60. The stock has a market cap of $402.99 billion, a PE ratio of 17.90, a price-to-earnings-growth ratio of 2.10 and a beta of 0.41.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. The company had revenue of $23.74 billion during the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%. Johnson & Johnson's revenue for the quarter was up 5.8% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.82 EPS. On average, equities research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be given a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a yield of 3.1%. Johnson & Johnson's dividend payout ratio is presently 55.61%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.